Statement on Passing of Dr. Marc Chevrier, a Lupus Research Pioneer

The Lupus Foundation of America joins the global lupus community in mourning the passing of lupus clinical researcher Dr. Marc Chevrier. As a member of the team at Human Genome Sciences in Rockville, Maryland. Dr. Chevrier was a leader in efforts to develop Benlysta®, which in 2011 became the first-ever drug developed specifically for lupus to receive approval by the U.S. Food and Drug Administration. More recently, Dr. Chevrier was a senior member of the team at Janssen R&D, LLC (Johnson & Johnson) where served as head of lupus-portfolio strategy. 

Marc Roger Chevrier, PhD, MD, FACR was board certified in rheumatology and internal medicine. He held a longtime interest in making a difference in people’s lives by solving the challenges presented by autoimmune diseases and surrounding issues. He was the author, corresponding author, co-author, or contributor to more than two dozen scientific/medical articles or research papers and received numerous awards and industry recognitions for his contributions to the field. His distinguished career included serving as an assistant Professor at the University of Maryland School of Medicine, and fellowships at Johns Hopkins University and the National Institutes of Health.

The Lupus Foundation of America offers our sincere condolences to his family, co-workers, professional colleagues and everyone who has been affected in some way by his life’s important work.